Quantcast

Latest Halozyme Therapeutics Inc. Stories

2014-08-04 16:26:54

SAN DIEGO, Aug. 4, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2014 on Monday, August 11, 2014 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the second quarter 2014. The call will be webcast live through the "Investors" section of Halozyme's corporate website...

2014-07-22 08:32:36

Additional Independent Review Board Approvals Expected for Phase 2 Trial (Study 202) SAN DIEGO, July 22, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical protocol agreed to with the FDA in June. PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant...

2014-07-10 08:27:24

Editor Note: For more information about this release, please scroll to bottom. LONDON, July 10, 2014 /PRNewswire/ -- On Wednesday, July 09, 2014, the NASDAQ Composite ended at 4,419.03, up 0.63%, the Dow Jones Industrial Average advanced 0.47%, to finish the day at 16,985.61, and the S&P 500 closed at 1,972.83, up 0.46%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 712.05, up...

2014-06-25 08:30:51

MabThera SC offers a faster administration time for patients in Europe while potentially saving valuable time for health systems SAN DIEGO, June 25, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the commercial launch of MabThera(®) SC in Europe has triggered a $5 million milestone payment to Halozyme during the second quarter under the License and Collaboration Agreement between Halozyme and Roche. Following the launch of Herceptin(®) SC in...

2014-06-17 16:26:22

SAN DIEGO, June 17, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the JMP Securities 2014 Healthcare Conference in New York, NY, on Tuesday, June 24, 2014 at 2:30 p.m. ET/11:30 a.m. PT. David Ramsay, Chief Financial Officer, will provide a corporate overview. The presentation will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and a recording will be made available for 90 days following the...

2014-06-15 16:20:33

CONSISTENT 1 Trial Results Presented in Late-Breaker Poster SAN DIEGO, June 15, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today presented a scientific poster highlighting the CONSISTENT 1 trial results at the 74th Scientific Sessions of the American Diabetes Association in San Francisco. The CONSISTENT 1 trial is evaluating Hylenex(®) recombinant and a new formulation of Hylenex currently under U.S. Food and Drug Administration (FDA) review, when used as...

2014-06-04 16:26:01

FDA Removes Clinical Hold on Phase 2 Trial (Study 202) SAN DIEGO, June 4, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on patient enrollment and dosing of PEGPH20 in the ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer permitting the study to resume under a revised protocol. Patient enrollment is anticipated to recommence upon review...

2014-05-29 16:26:55

SAN DIEGO, May 29, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Jefferies 2014 Global Health Care Conference in New York, NY, on Thursday, June 5, 2014 at 12:30 p.m. ET/9:30 a.m. PT. Dr. Helen Torley, Chief Executive Officer, will provide a corporate overview. The presentation will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and a recording will be made available for 90 days following the...

2014-05-14 20:23:36

SAN DIEGO, May 14, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the UBS 2014 Global Health Care Conference in New York, NY, on Tuesday, May 20, 2014 at 3:00 p.m. ET/12:00 p.m. PT. David Ramsay, Chief Financial Officer, will provide a corporate overview. The presentation will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and a recording will be made available for 90 days following the event. To...

2014-05-14 12:25:24

Editor Note: For more information about this release, please scroll to bottom LONDON, May 14, 2014 /PRNewswire/ -- The US markets saw a mixed sentiment on Tuesday, May 13, 2014, with the NASDAQ Composite closing at 4,130.17, down 0.33%, the Dow Jones Industrial Average ending the session at 16,715.44, up 0.12% and the S&P 500 edging 0.04% higher to finish the trading session at 1,897.45. The session saw a positive impact from Energy, Industrials and Consumer Staples sectors...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related